Evidence map›Paper›PMID 29304158›Full record

ArticlePloS one2018

Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels.

Toshiro Kitagawa, Noboru Oda, Mariko Mizukawa, Takayuki Hidaka, Makiko Naka, Susumu Nakayama, Yasuki Kihara

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Toshiro KitagawaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan.ORCID 0000-0002-5433-2428
Noboru OdaDepartment of Cardiology, Hiroshima City Asa Hospital, Hiroshima, Japan.
Mariko MizukawaHeart Failure Center, Hiroshima University Hospital, Hiroshima, Japan.
Takayuki HidakaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan.
Makiko NakaHeart Failure Center, Hiroshima University Hospital, Hiroshima, Japan.
Susumu NakayamaHeart Failure Center, Hiroshima University Hospital, Hiroshima, Japan.
Yasuki KiharaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan.
Hiroshima University · JPHiroshima University Hospital · JPHiroshima City Asa Citizens Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with heart failure (HF) are reportedly at high risk for 'all-cause' re-hospitalization. A biomarker for HF, N-terminal pro-brain natriuretic peptide (NT-proBNP), enables to simply detect patients with possible HF (pHF). We examined the hospitalization and medical cost of Japanese patients detected by an elevated serum NT-proBNP, and also evaluated the effects of institutional team approaches for HF on their all-cause hospitalizations.

methodsWe retrospectively extracted all adult patients with serum NT-proBNP ≥400 pg/ml measured between January and March 2012 in Hiroshima University Hospital as pHF-positive patients. We studied their all-cause hospitalization records during the past 3-year period. We also extracted all pHF-negative patients with NT-proBNP <400 pg/ml and studied as well. In the pHF-positive patients followed for 3 years after starting interprofessional team approaches to prevent the onset and exacerbation of HF in the hospital, we compared the hospitalization and medical cost between the 3-year periods before and after the start of the team approaches.

resultsWe enrolled 432 pHF-positive and 485 pHF-negative patients with one or more hospitalization records. Compared to the pHF-negative patients, the pHF-positive patients had longer total hospitalization days (median [interquartile range], 30 [13-58] versus. 18 [8-39], p <0.0001) and higher total medical cost for hospitalizations (2.42 [1.07-5.08] versus. 1.80 [0.79-3.65] million yen, p <0.0001). A subset of 303 pHF-positive patients was followed for 3 years after starting the team approaches, and we found that both total hospitalization days (30 [13-57] to 8 [0-31]) and medical cost for hospitalizations (2.59 [1.37-5.05] to 0.76 [0-2.38] million yen) showed marked reduction in them.

conclusionsPatients with an elevated serum NT-proBNP have longer hospitalizations and higher costs for all-cause hospitalizations than those without. Institutional team approaches for HF may reduce them.

Indexed as

Hospital CostsHospitalizationAgedFemaleHeart FailureHumansLength of StayMaleMiddle AgedNatriuretic Peptide, BrainNatriuretic Peptide, Brain

Identifiers

PMID29304158
PMCPMC5755927
OpenAlexW2781774559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.